The present invention relates to air treatment systems and, more specifically, to an air purification system that can reliably eliminate airborne pathogens in a given location.
The current global COVID-19 pandemic has revealed the need for systems that can address airborne pathogens including viruses. For example, enclosed locations including rooms, building, and even vehicle such as those used for public transportation must remain safe to remain open during a pandemic or to be placed back into use after quarantining periods have ended and governments allow reopening. Current cleaning methods, such as ultraviolet (UV) radiation of surfaces can provide significant improvements to reduce spread of contagions, but there is still vast room for improvement. One significant risk point is the inability of conventional HVAC and air treatment systems to effectively filter out airborne viruses, including COVID-19.
The present invention provides an air purification system for use in an enclosed location that can reliably remove or destroy harmful pathogens. More specifically, the air purification system comprises a housing having an inlet, an outlet, and a passageway extending between the inlet and the outlet within the housing to define an air flow pathway. At least one fan is positioned in the housing to create and maintain a pressure differential along the passageway such that air can flow into the inlets, through the passageway, and out of the outlet along the air flow pathway. An intense field unit is coupled to the inlet, wherein the intense field unit comprises an intense field generator having a series of openings formed therethrough and a corresponding series of electrodes positioned in each of the series of openings so that a tip of each electrode extends into a center of each opening respectively, and an intense field dielectric filter having a plurality of channels formed therethrough and aligned with the openings of the intense field generator, wherein each channel is defined by a first surface comprising a first electrode and a second surface opposing the first electric and comprises a second electrode, and wherein the first electrode and the second electrode are encompassed by a dielectric material. A dielectric barrier discharge unit having a high voltage electrode coupled to a dielectric barrier and a ground electrode spaced apart from the high voltage electrode to define a low temperature plasma discharge chamber has the discharge chamber is in communication with the passageway to treat the air in the passageway with a plasma discharge. A first power source is coupled to the intense field generator to apply a first voltage to the tip of each electrode and to an edge of each opening that is sufficient to create a corona discharge therebetween. The voltage applied to the tip of each electrode and an edge of each opening is about 8000 volts of direct current. A second power source is coupled to the intense field dielectric filter to apply a second voltage to the first electrode and the second electrode. The second voltage is 24 volts of direct current. The channels are configured to result in a pressure drop in the air flow path of less than about 30 Pascals
The present invention also includes a method of purifying the air in a location. The first step is positioning an air treatment unit in the location, wherein the air treatment unit includes a housing having an inlet, and an outlet, and a passageway extending between the inlet and the outlet to define an air flow pathway, at least one fan positioned in the housing in the passageway, an intense field dielectric unit associated with the inlet, and a dielectric barrier discharge unit in communication with the passageway. In another step, the fan is operated to create and maintain a pressure differential along the passageway so that air flows from the location into the inlet, along the passageway, and out of the outlet into the location. The intense field generator is powered to create a corona discharge. The intense field filter is powered to capture any particles in the air that flows through the passageway that are charged by the corona discharge. The dielectric barrier discharge unit is powered to emit low temperature plasma into the passageway.
The present invention will be more fully understood and appreciated by reading the following Detailed Description in conjunction with the accompanying drawings, in which:
Referring to the figures, wherein like numeral refer to like parts throughout, there is seen in
Referring to
Referring to
Referring to
Referring to
Referring to
System 10 may further comprise a local controller programmed to dynamically operate any one or more of intense field dielectric phase 32 and dielectric barrier discharge phase 34 according to current conditions. For example, it may be possible to determine the current quality of the air to determine real-time demands of the location so that system 10 is operated at maximum efficiency to ensure adequate air purification while reducing power consumption, extending the lifespan of the components, and maximizing service intervals. In addition, visual indicators may be used to indicate to consumers the status of system 10, such as whether air purification is active and fully operational. System 10 may contain an hour meter to display the number of operational hours the unit has been active for, in order to help dictate maintenance periodicity.
Intense field dielectric units 32 and a dielectric barrier discharge phase 34 work harmoniously to provide germicidal irradiation, physical filtration to remove particles and reduce virus transmission, and disinfection through the release of disinfection factors (positive and negative oxygen ions). The solution of the present invention thus can effectively reduce the infection risk and range of a pathogen such as a virus, while also serving as a mechanism for disinfection of the enclosed location.
The synergistic effects of the combination of intense field dielectric filters 32 and a dielectric barrier discharge phase 34 of system 10 were evaluated and demonstrated with respect to removing/eliminating aerosolized MS2 Bacteriophage ATCC 15597-B1, as well as E. coli ATCC K-12. The efficiency of the device in an aerosol test study was evaluated to determine the effectiveness of the device to eliminate COVID-19. The efficacy of system 10 to eliminate aerosolized viruses in ISO 17025 accredited United States based laboratory testing in compliance with the EPA and FDA guidelines. Accordingly, two sets of testing were completed to validate the efficacy of system 10 to indicate personnel protection against COVID-19 and against other various viruses, bacteria, and hazardous airborne particulates.
In a first test, system 10 comprised intense field dielectric filter 32 and dielectric barrier discharge phase 34, with a text box and cabling for actuation of the individual subsystems. The unit included recirculated and supply air sections to demonstrate system 10 integrated into a baseline representative model. System 10 was tested using 15, 30 and 60 minute contact times with the MS2 bacteriophage ATCC 15597-B1. A first set of testing at the longer contact times was intended to provide validation results in a comparable format with other products, which were tested under similar parameters. Six total test runs were performed in single replicate for device runs and triple replicate aerosolized sample collection to evaluate efficacy to remove/inactivate the MS2 bacteriophage ATCC 15597-B1 from the air, including a control run and various combinations of the devices.
The MS2 was first inoculated and then aerosolized into the test chamber via nebulizers for 60 minutes to reach appropriate concentration, then baseline samples were taken at t=0 min, and additional samples were then taken at t=15 min, t=30 min, and t=60 min. After the samples were collected, they were plated and incubated and then enumerated to determine microbial concentration. Additional testing at shorter contact times was carried out using the MS2 and E. Coli in single replicate sampling at 1, 3, and 5 minutes. In total, 6 test runs were performed again under a similar process as described above.
The testing was performed with MS2 Bacteriophage, which is a small, non-enveloped virus that is recognized by the EPA as one of the most difficult type of viruses to inactivate and therefore considered by the EPA to be a representative viral screening tool. Specifically, there is a hierarchy that is generally applied to categorize these, which includes: (1) Small, non-enveloped viruses—most difficult to inactivate (MS2 Bacteriophage fits in this categorization) e.g. poliovirus, enterovirus, or rhinovirus; (2) Large, non-enveloped viruses—moderately difficult to inactivate e.g. adenovirus, rotavirus, or papillomavirus; and (3) Enveloped viruses—easy to inactivate (COVID-19 fits this categorization) e.g. influenza, herpes virus, or hepatitis virus.
For all runs, 0.5 ml of MS2 bacteriophage ATCC 15597-B1 stock and 10.0 ml of E. coli ATCC K-12 culture were added to 34.5 ml of Phosphate Buffered Saline and mixed until homogeneous. 20.0 ml of inoculum was added to each nebulizer. MS2 virions are 23-28 nm in diameter and non-enveloped, compared to the COVID-19 virus, which is 60-140 nm in diameter and enveloped. Therefore, it is harder to capture the MS2, more difficult to irradiate in terms of surface area, and requires significantly more radiation to inactivate. On this predication of the testing and its relevance for the intended application, the results presented can be construed to represent the minimum efficacy against COVID-19 and other flu-like viruses.
Air samples were taken in single replicate at the following time points after the device was running: 1 minute, 3 minutes and 5 minutes. Device was turned off after 5 minutes of total treatment time and samplers were allowed to continue sampling. Test microorganisms were grown on appropriate media. Cultures used for test inoculum are evaluated for sterility, washed and concentrated in sterile phosphate buffered saline upon harvesting. The test inoculum was split into two equal parts and added to the appropriate number of nebulizers. Liquid culture did not exceed 20 ml per nebulizer. The device was setup per protocol requirements and operated per manufacturer's instructions. The chamber is setup and the safety checklist was completed prior to test initiation. Test was initiated by aerosolizing the microorganisms per the nebulizers and allowing the concentration to reach the required PFU/m3. Once the concentration was reached, a time zero sample was taken, then the device was operated for the specified contact time and an additional sample was taken for each contact time. A decontamination process was run, 4 hours of UV exposure, prior to any humans entering the testing chamber. Samples were enumerated using standard dilution and plating techniques. Microbial concentrations were determined after appropriate incubation times. Reductions of microorganisms are calculated relative to concentration of the time zero or corresponding control run sample as applicable.
System 10 achieved a significant reduction in the aerosolized virus in a very short time interval. After just five minutes, the system reaches 99.98%, which is approximately a sanitation level equivalent to using standard hand sanitizer (99.99%). At 15 minutes, system 10 achieved a 99.99993% elimination of virus, approaching sterilization levels as it is increasing to a >99.99998% reduction after 30 minutes, and continuing >99.99998% through the 60-minute test period. Additional testing was performed as E. Coli at the shorter contact times to provide another live microorganism example to demonstrate the efficacy against bacterium. The system reached up to 99.998% efficacy as soon as one minute. The result demonstrate that system 10 acts to filter and purify the air and is effective not only on the immediate threat of the COVID-19 virus but that it will provide the same level of protection against other virus that recur annually in cold and flu season.
Table 1 below provides the test results for MS2 Bacteriophage ATCC 15597-B1 and system 10 with intense field dielectric filter 32 and dielectric barrier discharge phase 34.
1The Log reductions for the Test Runs are adjusted to account for natural die-off and gravitational settling observed in the Control Run.
2The Percent reductions for the Test Runs are adjusted to account for the natural die-off and gravitational settling observed in the Control Run.
Table 2 below provides the detailed test results for MS2 Bacteriophage ATCC 15597-B1 and system 10 with shorted contact times:
1The Log reductions for the Test Runs are adjusted to account for natural die-off and gravitational settling observed in the Control Run.
Table 3 below provides the detailed test results for E. coli ATCC K-12 and system 10.
1The Log reductions for the Test Runs are adjusted to account for natural die-off and gravitational settling observed in the Control Run.
By deploying system 10, it is possible to reduce intense cleaning regimes that have been put in place and provide an independently validated filtration and purification system that will begin to restore confidence and encourage the use of indoor locations.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2021/037342 | 6/15/2021 | WO |
Number | Date | Country | |
---|---|---|---|
63039622 | Jun 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17195867 | Mar 2021 | US |
Child | 18010705 | US |